Neil Goldenberg, M.D., Ph.D., professor of pediatrics and medicine with the Johns Hopkins University School of Medicine, has been named associate dean for research at Johns Hopkins All Children’s Hospital.

In July 2012, Goldenberg was recruited to Johns Hopkins All Children’s to assume the role of director of research. In December 2012, he founded the hospital’s Clinical and Translational Research Organization, and since that time has also served as chief research officer of the All Children’s Research Institute, the director of the Thrombosis Program in the hospital’s Cancer & Blood Disorders Institute, and the director of the Stroke Program in the Institute for Brain Protection Sciences.

Goldenberg is internationally recognized for his expertise and accomplishments in designing and conducting multicenter clinical trials, with a focus on improving children’s health. However, his research background extends from clinical research to basic science. Early in his pre-medical and medical career, his research training and experience focused on laboratory science, including investigation of chemotherapy drug resistance in human tumor-derived cell cultures and the application of molecular biology techniques for insertion of genes encoding tumor-associated proteins into attenuated viral vectors for development of potential cancer vaccines. From 2005-2012, he served as co-principal investigator of the Coagulation Research Laboratory at the University of Colorado Denver (UCD)-based Mountain States Regional Hemophilia and Thrombosis Center, where his grant-funded work on the development and application of novel assays of blood clot formation and breakdown yielded new insights on bleeding- and clotting-prone conditions in children and adults.

Goldenberg has authored more than 120 original research reports, review articles and book chapters, mostly as the lead or senior author. He is also the co-editor of a definitive textbook on pediatric thrombotic disorders, published by Cambridge University Press. In addition, Goldenberg has given national and international invited lectures, webinars, and workshop presentations on behalf the U.S. Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the Food and Drug Administration (FDA).

Currently, Goldenberg serves as overall principal investigator for the NIH-sponsored Kids-DOTT trial, a multinational randomized controlled trial investigating the optimal duration of anticoagulation (anti-clotting medication) for venous thromboembolism (blood clots in the veins) in patients under 21 years of age. He also serves as chair of the Independent Data and Safety Monitoring Committee for several international, FDA-regulated pediatric clinical trials being conducted by the pharmaceutical industry. At Hopkins, Goldenberg also leads a team of physician faculty members conducting multiple investigator-initiated, longitudinal cohort and biobanking studies across a spectrum of childhood diseases, some of which have extended to the Johns Hopkins Children’s Center and Johns Hopkins Bayview medical campus in Baltimore. In addition, he co-leads (with Baltimore-based faculty colleague Sara Johnson, Ph.D.) a birth cohort study spanning St. Petersburg and Baltimore, funded by the NIH, the Johns Hopkins All Children’s Foundation, and the Department of Pediatrics at the Johns Hopkins University School of Medicine.

As a proud graduate of the USF Combined Residency Program in Internal Medicine and Pediatrics (inaugural class of 2002), Goldenberg completed a significant portion of his clinical training in the Tampa Bay area. His move to St. Petersburg in 2012 with his family was a homecoming, and some of his greatest professional joys during the past seven years have been the opportunities taken to collaborate with and mentor earlier-career faculty and trainees at both USF and JHU-Baltimore, in addition to those at Johns Hopkins All Children’s. In a recent research staff meeting, Goldenberg expressed his tremendous enthusiasm for what the next seven years hold for the hospital’s research, with a vision and focus on fostering scientific discoveries and therapeutic advances that will improve children’s health locally, nationally and around the world.